Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciprofibrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA known ✓ | Q07869 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 7/20 | 0.50 |
| ▸ | FABP2 | P12104 | 2/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprofibrate SCHEMBL8164529 | 1.00 | PPARA (1.00) | PPARALMNATSHRCYP2C9BLM | |
| SCHEMBL21391383 | 0.88 | PPARA (0.78) | PPARALMNATSHRCYP2C9BLM | |
| SCHEMBL9779928 | 0.85 | LMNA (0.74) | PPARALMNATSHRCYP2C9BLM | |
| SCHEMBL11013173 | 0.82 | PPARA (0.69) | PPARALMNATSHRCYP2C9BLM | |
| SCHEMBL10598812 | 0.81 | PPARA (0.67) | PPARALMNATSHRCYP2C9BLM | |
| SCHEMBL21413780 | 0.81 | LMNA (0.67) | PPARALMNATSHRCYP2C9BLM | |
| Clinofibrate SCHEMBL7620220 | 0.80 | ADORA3 (0.71) | PPARALMNATSHRCYP2C9BLM | |
| Fenofibrate SCHEMBL6901888 | 0.80 | PPARA (0.69) | PPARALMNATSHRCYP2C9BLM | |
| SCHEMBL5315412 | 0.80 | LMNA (0.67) | PPARALMNATSHRCYP2C9BLM | |
| Bezafibrate SCHEMBL7079797 | 0.79 | PPARA (0.77) | PPARALMNATSHRCYP2C9BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 12498 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| US-12582626-B2 | Methods and compositions for treating cancer | The Wister Institute of Anatomy and Biology (US) | 2026-03-24 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250367216-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250367217-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | claimed |
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250345333-A1 | THERAPIES WITH PPAR AGONISTS AND FGFR4 INHIBITORS | TYRA BIOSCIENCES INC (US) | 2025-11-13 | — | — | US | claimed |
| US-20250339501-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASE | UNIV CALIFORNIA (US) | 2025-11-06 | — | — | US | claimed |
| US-20250312353-A1 | DRUG REPURPOSING FOR TREATMENT OF CONGENITAL VASCULAR MALFORMATIONS | UNIVERSITY OF SOUTH CAROLINA (US) | 2025-10-09 | — | — | US | claimed |
| US-5476965-A | Reacting with esterhydrolase or protease | GENENCOR INTERNATIONAL, INC. (US) | 1995-12-19 | — | — | US | claimed |
| WO-1995022620-A1 | ENZYMATIC RESOLUTION OF SUBSTITUTED 2-METHYL-PROPIONIC ACID | GENENCOR INTERNATIONAL, INC. (US) | 1995-08-24 | — | — | WO | claimed |
| US-5179097-A | Salts of non-steroidal anti-inflammatory carboxylic acids and anti-lipidemic carboxylic acids | ANGRES ISAAC A (US) | 1993-01-12 | — | — | US | claimed |
| EP-0508665-A2 | Use of ACE inhibitors for lowering serum cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-10-14 | — | — | EP | claimed |
| EP-0482498-A2 | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1992-04-29 | — | — | EP | claimed |
| EP-0475148-A1 | Pravastatin alone or in combination with a fibric acid derivative for preventing onset of or treating type III hyperlipoproteinemia | E.R. SQUIBB & SONS, INC. (US) | 1992-03-18 | — | — | EP | claimed |
| EP-0457514-A1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0455042-A1 | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination | E.R. SQUIBB & SONS, INC. (US) | 1991-11-06 | — | — | EP | claimed |
| US-5011986-A | Dextro-ciprofibrate | STERLING DRUG INC. (US) | 1991-04-30 | — | — | US | claimed |
| US-5011985-A | Levo-ciprofibrate | STERLING DRUG INC. (US) | 1991-04-30 | — | — | US | claimed |